fluoxetine has been researched along with Neurally Mediated Faint in 5 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 9.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| " Fluoxetine is effective against anxiety and panic disorders, while its use has shown promising results for VVS." | 5.24 | Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. ( Flevari, P; Katsaras, D; Katsimardos, A; Leftheriotis, D; Lekakis, J; Repasos, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Behnoush, AH | 2 |
| Yazdani, K | 2 |
| Khalaji, A | 2 |
| Tavolinejad, H | 2 |
| Aminorroaya, A | 2 |
| Jalali, A | 2 |
| Tajdini, M | 2 |
| Flevari, P | 2 |
| Leftheriotis, D | 2 |
| Repasos, E | 1 |
| Katsaras, D | 1 |
| Katsimardos, A | 1 |
| Lekakis, J | 1 |
| Ariturk, Z | 1 |
| Alici, H | 1 |
| Cakici, M | 1 |
| Davutoglu, V | 1 |
| Theodorakis, GN | 1 |
| Livanis, EG | 1 |
| Karabela, G | 1 |
| Aggelopoulou, N | 1 |
| Kremastinos, DT | 1 |
| Chen, LY | 1 |
| Shen, WK | 1 |
2 reviews available for fluoxetine and Neurally Mediated Faint
| Article | Year |
|---|---|
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Pharmacologic prevention of recurrent vasovagal syncope: A systematic review and network meta-analysis of randomized controlled trials.
Topics: Fluoxetine; Humans; Midodrine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Syncope | 2023 |
Neurocardiogenic syncope: latest pharmacological therapies.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Atenolol; Blood Pressure; Fluoxetine; Heart | 2006 |
2 trials available for fluoxetine and Neurally Mediated Faint
| Article | Year |
|---|---|
Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity.
Topics: Adult; Anti-Anxiety Agents; Anxiety; Cardiovascular Agents; Female; Fluoxetine; Greece; Humans; Male | 2017 |
Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study.
Topics: Adrenergic beta-Antagonists; Adult; Attitude to Health; Double-Blind Method; Female; Fluoxetine; Hum | 2006 |
1 other study available for fluoxetine and Neurally Mediated Faint
| Article | Year |
|---|---|
A rare cause of syncope: cough.
Topics: Antidepressive Agents, Second-Generation; Cough; Fluoxetine; Gastroesophageal Reflux; Humans; Male; | 2012 |